Please login to the form below

Not currently logged in

Takeda’s HAE drug Takhzyro backed by NICE

New treatment option for rare, hereditary disease


Takeda’s drug for the rare disease hereditary angioedema (HAE) should be made available routinely on the NHS in England and Wales, says NICE.

The cost-effectiveness agency has issued its final appraisal document for Takhzyro (lanadelumab) as an injectable treatment option for preventing recurrent attacks in type I/II HAE patients aged 12 and over, provided they are having two or more clinically significant attacks per week despite the use of oral prevention drugs.

According to the guidance document, Takhzyro should be used at the lowest-dose possible, and can only be prescribed subject to a confidential pricing and access deal between Takeda and the NHS.

HAE is a genetic disorder that can cause unpredictable attacks of debilitating and painful swelling in various parts of the body which can last for a number of days. Attacks that obstruct the airways can cause suffocation and are potentially life-threatening.

First-line preventive treatment is with oral drugs like danazol and oxandrolone, and with C1 esterase inhibitors like Takeda’s intravenous Cinryze and CSL Behring’s injectable Berinert that are also used to treat swelling once it has become established. Cinryze is approved for prevention, and while Berinert isn’t, NICE says the drug is sometime prescribed off-label for this purpose.

That makes Takhzyro the first self-injected subcutaneous treatment to be approved for use in attack prevention, says Takeda UK, and so provides a more convenient treatment option for patients.

“HAE attacks are unpredictable, painful and debilitating. [The] recommendation from NICE means that people living with HAE across England and Wales have another medication that gives them the chance to lead a full and active life,” said Laura Szutowicz, chief executive of medical charity HAE UK.

“We hope the NHS and healthcare professionals will provide swift access to patients who could benefit from this new treatment,” she added.

Like Firazyr and Cinryze, Takhzyro was originally developed by Shire, which has been absorbed by Takeda in a $63bn takeover.

Analysts have predicted that Takhzyro could make up to $2bn in peak sales. It’s given as a subcutaneous injection that takes less than a minute to deliver every two weeks, requiring around 75% fewer injections than other products for HAE prevention.

Article by
Phil Taylor

19th September 2019

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...